Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
Jul 8, 2026, 11:33Ifeanyichukwu Ifechidere: Haemophilia A and B – From First Diagnosis to the Era of Gene Therapy
-
Jul 8, 2026, 10:29Bringing Hemophilia Care Closer to Communities in Togo – WFH
-
Jul 8, 2026, 10:12Natasha Jolakoski: Completing Advanced Training in Thrombosis and Hemostasis
-
Jul 8, 2026, 09:58Rola Ghasoub: Early Intracranial Hemorrhage Remains the Main Barrier to Cure in Acute Promyelocytic Leukemia
-
Jul 8, 2026, 05:53Excellent PhD Defense by Roberta Cirsmaru on Gene Therapy for Hemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Jul 8, 2026, 05:48Riccardo Menandro: How Lipid Nanoparticles Are Shaping the Future of Rare Disease and Hemophilia Treatment
-
Jul 8, 2026, 05:39Daniel Victor Ortigoza: New Evidence from ATLANTIS-4D-CT on Apixaban and Subclinical Valve Thrombosis
-
Jul 8, 2026, 04:50Reza Bavarsad Shahripour: New AHA Guidance on Cryptogenic Stroke with Reduced Left Ventricular Function
-
Jul 7, 2026, 23:20Balaji Balagani: Exploring Pulmonary Embolism